Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clofarabine Pre-Conditioning Before Allogeneic Transplantation in High-Risk AML and MDS
2008-007043-14Phase 2Unknown
- Sponsor
- University Hospital Southampton NHS Foundation Trust
- Start
- Aug 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of clofarabine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by University Hospital Southampton NHS Foundation Trust. Primary endpoints: Treatment-related mortality at day 100 post-transplant and Treatment-related mortality at 1 year post-transplant. Status: unknown.
02
Drugs
clofarabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2008-007043-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007043-14.